Clinical Trial

Study of the Efficacy and Safety of Etanercept Treatment in Patients With SAPHO Syndrome

Study acronym: SAPHO
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The study includes adult patients with SAPHO syndrome (ORPHA: 793), meeting the modified classification criteria according to Kahn (2003), with the ineffectiveness of standard treatment (patient's global assessment of the disease on the VAS scale greater than or equal to 4 cm with accompanying pain on the VAS scale greater than or equal to 4 cm) treated with non-steroidal anti-inflammatory drugs in a stable dose for at least 4 weeks and/or classical disease-modifying antirheumatic drugs in stable doses for at least 12 weeks.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-08-21; most recent amendment 2026-04-07.
Trial Details
NCT Number NCT06011889
Lead Sponsor National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland
Collaborators: Medical Research Agency, Poland
Conditions SAPHO Syndrome
Enrollment 60 participants
Start Date 2024-09-04
Primary Completion 2028-10-18 (estimated)
Study Completion 2028-10-18 (estimated)
Updated on ClinicalTrials.gov 2026-04-13